Phoenix Financial Ltd. Decreases Position in Kamada Ltd. (NASDAQ:KMDA)

Key Points

• Phoenix Financial Ltd. reduced its stake in Kamada Ltd. by 9.7%, selling 178,000 shares and now holding approximately 1.65 million shares, representing about 2.88% of the company worth $11.27 million.
• Recent analyst activity includes upgrades by Wall Street Zen from "buy" to "strong-buy" and a "buy" rating from Benchmark with a target price of $15.00 for Kamada shares.
• Kamada Ltd. reported quarterly earnings of $0.07 per share, meeting analysts' expectations, but with revenue of $44.02 million falling short of the consensus estimate of $154.06 million.

Phoenix Financial Ltd. lessened its holdings in shares of Kamada Ltd. (NASDAQ:KMDA - Free Report) by 9.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,654,952 shares of the biotechnology company's stock after selling 178,000 shares during the period. Phoenix Financial Ltd. owned approximately 2.88% of Kamada worth $11,270,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the 4th quarter valued at $67,000. NewEdge Advisors LLC lifted its holdings in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after purchasing an additional 8,260 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kamada by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Aristides Capital LLC lifted its holdings in shares of Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock valued at $387,000 after purchasing an additional 6,850 shares during the last quarter. Finally, Huntleigh Advisors Inc. purchased a new stake in shares of Kamada during the 1st quarter valued at $863,000. Hedge funds and other institutional investors own 20.38% of the company's stock.

Analyst Upgrades and Downgrades

KMDA has been the subject of a number of research analyst reports. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, May 21st. Sidoti upgraded Kamada to a "hold" rating in a research note on Thursday, May 8th. Finally, Benchmark restated a "buy" rating and issued a $15.00 target price on shares of Kamada in a research note on Thursday, May 15th.

Kamada Price Performance

Shares of KMDA stock opened at $7.78 on Friday. The business has a fifty day moving average of $7.30 and a 200 day moving average of $7.04. The firm has a market capitalization of $447.43 million, a price-to-earnings ratio of 26.83, a price-to-earnings-growth ratio of 0.96 and a beta of 0.96. Kamada Ltd. has a 1 year low of $5.08 and a 1 year high of $9.15.

Kamada (NASDAQ:KMDA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. The company had revenue of $44.02 million for the quarter, compared to the consensus estimate of $154.06 million. Kamada had a return on equity of 6.31% and a net margin of 9.60%. As a group, equities research analysts expect that Kamada Ltd. will post 0.23 earnings per share for the current year.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

Want to see what other hedge funds are holding KMDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kamada Ltd. (NASDAQ:KMDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.